What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial evidence from the REDUCE-IT trial indicates that icosapent ethyl reduces the risk of cardiovascular events compared to placebo in patients with elevated triglycerides. However, the trial’s generalizability to the Healthcare is uncertain due to the lack of UK participants and potential biases introduced by the mineral oil placebo. While there is moderate benefit shown, the uncertainty surrounding the trial results prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The most plausible ICER for icosapent ethyl is between £21,750 and £24,821 per QALY gained, which is within the acceptable range for Healthcare resources. The committee noted that while there is uncertainty in the cost-effectiveness estimates, the treatment is likely to be cost-effective for secondary prevention, justifying an A rating.
Is there quality-of-life evidence payers weigh? — Quality of life
The document does not provide specific data on HRQoL improvements associated with icosapent ethyl. While the treatment is expected to reduce cardiovascular events, the absence of robust evidence demonstrating significant improvements in quality of life or validated patient-reported outcomes leads to a rating of B++.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Icosapent ethyl has a generally well-tolerated safety profile, with similar rates of adverse events compared to placebo. Although there are some concerns regarding specific adverse events like atrial fibrillation and bleeding-related events, the overall tolerability is considered good, warranting an A+ rating.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against an appropriate standard of care, specifically statins with or without ezetimibe, which is relevant for the target population. The committee agreed that this comparator is suitable given the lack of other treatment options for patients with elevated triglycerides on statins.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is moderately representative of the intended patient population, focusing on adults with established cardiovascular disease or diabetes and elevated triglycerides. However, the exclusion of younger patients and the potential for unequal representation of ethnic groups slightly limits generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Icosapent ethyl is expected to be integrated into existing care pathways with minimal disruption, as it is intended for use alongside statin therapy. The committee noted that it would likely be used primarily in a primary care setting, indicating a good fit within current clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of icosapent ethyl is manageable, and the treatment is expected to provide a good return on investment given its cost-effectiveness profile. The committee concluded that the resource implications are justifiable in the context of the expected health outcomes.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the REDUCE-IT trial provides substantial evidence, there are concerns regarding its generalizability and the potential biases introduced by the placebo used. The evidence base is solid but has notable limitations that prevent a higher rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the treatment effect due to the mineral oil placebo and the generalizability of the trial results. The committee expressed concerns about the implications of these uncertainties on the overall assessment, leading to a B+ rating.
